INmune Bio (INMB) to Announce Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.2067) per share and revenue of $1.1550 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

INmune Bio Trading Down 1.2%

Shares of INMB stock opened at $1.69 on Thursday. INmune Bio has a 1-year low of $1.09 and a 1-year high of $3.00. The stock has a market cap of $44.92 million, a price-to-earnings ratio of -1.01 and a beta of 0.97. The stock has a 50-day moving average of $1.56 and a 200-day moving average of $1.46.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wall Street Zen cut INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings upgraded shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after purchasing an additional 2,409 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of INmune Bio by 20.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after acquiring an additional 8,427 shares during the period. Royal Bank of Canada boosted its position in shares of INmune Bio by 44.8% during the 1st quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after purchasing an additional 9,236 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in INmune Bio by 79.0% in the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after acquiring an additional 10,970 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in INmune Bio in the 2nd quarter valued at $26,000. 12.72% of the stock is owned by institutional investors and hedge funds.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.